Johnson & Johnson Provides Justification To Stay On The Sidelines

According to Goldman Sachs, Johnson & Johnson JNJ was highlighted with risk as it headed into it's 2Q due to $0.11 below consensus rating and potential management guidance reduction for 2010 due to cost-restructuring challenges. Goldman has maintained Johnson & Johnson at "neutral". The key risks involved are (a) pharma pipeline delays, (b) collateral brand damage due to Consumer recall, and (c) EU pricing pressures. The upside risks are (a) pipeline approvals, and (b) cost restructuring benefits. Goldman says Abbott Laboratories ABT is the preferred diversified pharma company, expected to have higher quality 2Q earnings, lesser risk in reducing 2010 guidance, and a discounted 2011 PEG due to superior EPS growth. Stock prices yesterday quoted at $58.58.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsGuidanceMarketsAnalyst RatingsAbbottGoldman SachsJohnson & Johnsonpharmaceuticalspipeline
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!